TargetMol

Legumain Protein, Sus scrofa (Pig), Recombinant (His)

Product Code:
 
TAR-TMPY-02873
Product Group:
 
Recombinant Proteins
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20°C
1 / 1
❮❯

Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-TMPY-02873-50ug50ugEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Show All

Further Information

Bioactivity:
Legumain Protein, Sus scrofa (Pig), Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 49.7 kDa and the accession number is A0A287AW67.
Molecular Weight:
49.7 kDa (predicted)
Purity:
98%

References

1.Schwarz G,et al.(2002) Characterization of legumain. Biol Chem. 383(11): 1813-6. 2.Liu C,et al.(2003) Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy. Cancer Res. 63(11): 2957-64. 3.Murthy RV,et al.(2005) Legumain expression in relation to clinicopathologic and biological variables in colorectal cancer. Clin Cancer Res. 11(6): 2293-9. 4.Gawenda J,et al.(2007) Legumain expression as a prognostic factor in breast cancer patients. Breast Cancer Res Treat. 102(1): 1-6. 5.Clerin V,et al.(2007) Expression of the cysteine protease legumain in vascular lesions and functional implications in atherogenesis. Atherosclerosis. 201(1): 53-66. 6.Lew??n S,et al.(2008) A Legumain-based minigene vaccine targets the tumor stroma and suppresses breast cancer growth and angiogenesis. Cancer Immunol Immunother. 57(4): 507-15.